Verona Pharma: A 363% Return Thanks To Big Pharma's Myopia
Merck plans to acquire Verona Pharma for $10 billion, or $107 per share — a 363% gain for the Innovation & Freedom Portfolio.
Portfolio
Portfolio Update: Is This The Peak (For Now)?
Since its inception in August 2024, the I&F Portfolio has gained over 100%, outpacing the S&P 500 by 85%, driven by standout performances from Rocket Lab (RKLB), Verona Pharma (VRNA), Navitas Semiconductor (NVTS), and others.
Why Estimates For NVIDIA's Q4 Revenue Could Be Dead Wrong: The Case for NVIDIA's Next Blowout Report
Estimating NVIDIA's Q4 2025 revenue from the capex of its four largest customers using linear regression results in an estimated revenue that is significantly higher than Wall Street's expectations.
Powell Industries: Rooted in The Oil Boom, Ready For The AI Revolution
Powell Industries is poised to benefit from the growing need for sophisticated power distribution solutions for AI data centers, reshored manufacturing driven by robotics and automation, and a booming nuclear energy sector.
NVIDIA: No Reason To Panic
The recent sell-off in NVIDIA shows one thing above all, in my opinion: many of today's investors do not understand the companies they are investing in.
Jevons Paradox: DeepSeek-R1 Will Ultimately Drive Demand for NVIDIA's GPUs
In 1865, William Jevons observed that coal consumption in England was growing exponentially despite increasingly efficient steam engines. Similarly, in the coming years, more efficient AI models like DeepSeek-R1 could drive demand for NVIDIA's GPUs, not reduce it.
Journey Medical Corporation: Why It Might Be Worth Having A Skin In This Game
Journey Medical's newly approved Emrosi™ outperformed Oracea® in two Phase III trials. If it captures a significant share of Oracea's $300m market, Journey could be significantly undervalued.
Hermès International: Why Artisan Craftsmanship Is A Bet On The Dawning Technological Revolution
At the dawn of the AI age, Hermès is still focusing on craftsmanship and scarcity, which could make its luxury products increasingly desirable and valuable, especially in an era of rapid automation and commoditization of goods.
Portfolio Update: Full Speed Ahead For Another American Century
Since August, the I&F Portfolio is up more than 70% and has outperformed the S&P 500 by 50%, thanks to stellar performances of AppLovin (APP), Rocket Lab (RKLB), Esperion Therapeutics (ESPR), Navitas Semiconductor (NVTS) and Verona Pharma (VRNA), among others.
iPadOS 18.1 Bricked My Brand New iPad Pro (M4) - What's Wrong With Apple?
There have been issues with iPadOS 18 bricking devices for the past two months. While my problem was easily solved, it calls into question the usual perfection of Apple products.
AI: This "Bubble" Is Stuffed With Money
If there's an inflating AI bubble, it's a bubble stuffed with money. NVIDIA's earnings on August 28th could burst it again and unleash a cash bonanza for investors.
Time To Pick Some Stocks
Time for some optimism: After the recent sell-off, let's call it a bottom and put together a stock portfolio.